African Medicines Agency

In recent months, 15 African Union Member States have ratified the Treaty for the creation of the African Medicines Agency, which will ease the monitoring of safety and effectiveness of marketed medicines and vaccines across Africa. Following the Africa Centers for Disease Control and Prevention(Africa CDC), the African Medicines Agency will be the second cross-continental African ...

Webinar: Technological innovations for pharmacy in Africa amidst the Covid-19 pandemic

Dr. Prosper Hiag, who facilitated our last QUAMED member webinar, appealed to drug regulators in Africa at a regional workshop in Lagos, Nigeria. He asked them to enact laws to guide the practice of internet pharmacy across the continent. The event was held under the theme: “Technological innovations for pharmacy in Africa amidst the Covid-19 ...

The importance of Pharmacovigilance:

The collection and assessment of adverse reactions are important in the first decade after the marketing authorization of a drug. The information gathered in this period could help, for example, identify complications from its use that were unknown before its commercialization. However, when it comes to medicines that have been on the market for a ...

COVID-19 Vaccines Quality Report

COVID-19 vaccines are vital interventions to help end the pandemic. However, issues with equitable global access, falsified, diverted and substandard (especially degraded) vaccines are highly likely to become increasingly global public health problems.  Read the latest Medicine Product Quality Report on substandard and falsified (SF) COVID-19 vaccines, which summarise reports in the public domain including ...

Pharmaceutical Patents and Monopolistic Pricing

South Africa’s struggle to increase access to anti-retroviral medications decades ago focused attention on the relationship between patent protection and high medicine prices. The COVID-19 pandemic has drawn greater attention to the cost of pharmaceutical technologies and the inequitable access to these. Globally this has raised concerns about the impact of the 1994 World Trade ...

Fighting poor quality health products in times of Covid-19 and beyond: the need for a multi-stakeholder approach

World Health Organization (WHO) estimates from 2017 indicates that 10.5% of medical products available in low- and middle-income countries (LMICs) are “substandard or falsified” (SF). Substandard health products are approved by the national regulators, but they do not comply with adequate standards due to undetected errors, negligence, or poor practice in manufacturing, transportation, or storage. ...